A New Approach to Diabetes Cell Therapy Skips the Immunosuppression Problem

Researchers presented first-in-human results at the 2026 annual meeting of the International Society for Stem Cell Research (ISSCR) testing a new approach to cell replacement therapy for type 1 diabetes, an autoimmune disease in which the immune system destroys the insulin-producing cells in the pancreas. The study, led by Sonja Schrepfer, MD, PhD, of Cedars-Sinai Medical Center, evaluated whether lab-engineered, donor-derived insulin-producing cells could survive and function in the body without the lifelong immunosuppressive drugs that current cell therapies require.

Cell replacement therapy, which involves transplanting insulin-producing islet cells or stem cell-derived equivalents into a patient, has shown real promise for type 1 diabetes over the past several years, including a widely discussed stem cell therapy that reached the market recently. But there has always been a catch: because the transplanted cells come from a donor, the patient's immune system recognizes them as foreign and attacks them, the same underlying problem that caused their diabetes in the first place. To prevent rejection, patients typically need to take immunosuppressive medications for the rest of their lives, which carry their own risks, including higher rates of infection and certain cancers. That tradeoff has limited cell therapy to a relatively small group of patients whose diabetes is severe enough, or hard enough to control with insulin alone, to justify accepting those risks.

The cells tested in this study were engineered to be less visible to the immune system, an approach researchers call hypoimmune or immune-evasive engineering. Rather than relying on drugs to suppress the immune response after transplant, the cells themselves are modified at the genetic level to avoid triggering an attack in the first place. This first-in-human study was designed to test whether that engineering approach translates from lab and animal models into real patients, a critical and often difficult step in cell therapy development. Similar hypoimmune engineering strategies are also being explored by other research groups for organ and tissue transplantation more broadly, so lessons learned in this diabetes-focused study could have implications well beyond a single disease.

While full efficacy results were not the focus of this early presentation, the researchers described the findings as supportive of further development, addressing what they called one of the field's central challenges: overcoming immune rejection without chronic immunosuppression. If this approach continues to pan out in larger trials, it could eventually widen who is eligible for cell replacement therapy well beyond the current population, since many type 1 diabetes patients and their doctors are currently unwilling to accept the risks of lifelong immunosuppression for a condition that can already be managed, imperfectly, with insulin. It is still early-stage, first-in-human data, and much longer follow-up and larger patient numbers will be needed before this approach could become a mainstream treatment option.